ScholarIQanswers from OpenAlex
IRCCS Humanitas Research Hospital
InstitutionResearch output, impact & collaborations
IRCCS Humanitas Research Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about IRCCS Humanitas Research Hospital?
ScholarIQrecord summary
IRCCS Humanitas Research Hospital is a research organisation in Rozzano, IT. OpenAlex records 16,898 works and 993,669 citations for it. 4,269 researchers list it as their most recent affiliation.
How many works does IRCCS Humanitas Research Hospital have?
ScholarIQindexed works
IRCCS Humanitas Research Hospital has 16,898 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does IRCCS Humanitas Research Hospital have?
ScholarIQcitation count
IRCCS Humanitas Research Hospital has 993,669 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at IRCCS Humanitas Research Hospital?
ScholarIQresearcher count
IRCCS Humanitas Research Hospital has 4,269 researchers in the ScholarIQ index.
What is the average h-index at IRCCS Humanitas Research Hospital?
ScholarIQavg h-index
IRCCS Humanitas Research Hospital has an average h-index of 74 in OpenAlex.
What is the ROR of IRCCS Humanitas Research Hospital?
ScholarIQror
The ROR for IRCCS Humanitas Research Hospital is on the source record.
What is the OpenAlex record for IRCCS Humanitas Research Hospital?
ScholarIQopenalex
The OpenAlex for IRCCS Humanitas Research Hospital is on the source record.
Who are the most-cited researchers behind IRCCS Humanitas Research Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on IRCCS Humanitas Research Hospital?
ScholarIQmost cited works
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Chris Estes, Quentin M. Anstee, M. Arias, Heike Bantel, Stefano Bellentani, Joan Caballería, Massimo Colombo, Antonio Craxı̀, Javier Crespo, Christopher P. Day, Yuichiro Eguchi, Andreas Geier, Loreta A. Kondili, Daniela C. Kroy, Jeffrey V. Lazarus, Rohit Loomba, Michael P. Manns, Giulio Marchesini, Atsushi Nakajima, Francesco Negro, Salvatore Petta, Vlad Ratziu, Manuel Romero‐Gómez, Arun J. Sanyal, Jörn M. Schattenberg, Frank Tacke, Junko Tanaka, Christian Trautwein, Lai Wei, Stefan Zeuzem, Homie Razavi
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon, Enrico Lugli, Hugh C. Welles, Steven A. Rosenberg, Antonio Tito Fojo, John C. Morris, Thomas A. Fleisher, Sigrid Dubois, Liyanage P. Perera, Donn M. Stewart, Carolyn K. Goldman, Bonita R. Bryant, Jean M. Decker, Jing Chen, Tatyana Worthy, William D. Figg, Cody J. Peer, Michael C. Sneller, H. Clifford Lane, Jason L. Yovandich, Stephen P. Creekmore, Mario Roederer, Thomas A. Waldmann
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Jürgen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Santosh Sutradhar, Siyu Li, Tomasz Szczudlo, A. Yovine, Alice T. Shaw
How much of the research on IRCCS Humanitas Research Hospital is open access?
ScholarIQopen access share
56%OPEN ACCESS